We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
5 Reasons to Add Kronos Worldwide Stock to Your Portfolio
Read MoreHide Full Article
Kronos Worldwide’s (KRO - Free Report) stock looks promising at the moment. The chemical maker, currently carrying a Zacks Rank #1 (Strong Buy), has seen its shares pop roughly 56% year to date. If you haven’t taken advantage of the share price appreciation yet, the time is right for you to add the stock to portfolio as it looks promising and is poised to carry the momentum ahead.
What’s Working in Favor of Kronos?
Strong Q1 Performance & Upbeat Outlook: Kronos swung to a profit of $36.8 million or 32 cents per share in first-quarter 2017 from a loss of $3.8 million or 3 cents per share a year ago. Earnings per share topped the Zacks Consensus Estimate of 22 cents.
The results in the reported quarter were boosted by higher income from operations resulting from favorable impacts of improved selling prices, increased sales and production volumes and reduced raw materials and other production costs.
Revenues climbed 16% year over year to $369.8 million in the quarter, driven by higher titanium dioxide (TiO2) selling prices and increased sales volumes. Sales also surpassed the Zacks Consensus Estimate of $350 million.
Kronos envisions its production volumes to be higher in 2017 on a year over year basis as production rates this year will be favorably impacted by the implementation of certain productivity-enhancing improvement projects at some facilities. It also sees healthy demand for its TiO2 products across some of its primary markets.
Kronos also expects income from operations in 2017 will be higher on a year over year basis, mainly due to an expected increase in average selling prices and the favorable impact of anticipated higher production volumes in 2017.
An Outperformer: Kronos has significantly outperformed the Zacks categorized Chemicals-Diversified industry over a year, partly reflecting its forecast-topping earnings performance. The company’s shares have gained a whopping 209% over this period, compared with roughly 16.2% gain recorded by the industry.
Estimates Moving Up: Annual estimates for Kronos have moved north over the past 30 days, reflecting analysts’ confidence on the stock. Over this period, the Zacks Consensus Estimate for 2017 has increased by around 13.8% to 91 cents per share. The Zacks Consensus Estimate for 2018 has also moved up 17% over the same timeframe to $1.24.
Positive Earnings Surprise History: Kronos has an impressive earnings surprise history. The company has outpaced the Zacks Consensus Estimate in three of the trailing four quarters, delivering a positive average earnings surprise of 64.14%.
Healthy Growth Prospects: The Zacks Consensus Estimate for earnings for 2017 is currently pegged at 91 cents, reflecting an expected year-over-year growth of 192.5%. Moreover, earnings are expected to register a 36.2% growth in 2018. The stock also has a long-term (3-5 years) expected earnings per share growth rate of 5%.
Huntsman has an expected long-term earnings growth of 7%.
BASF has an expected long-term earnings growth of 8.6%.
Chemours has an expected long-term earnings growth of 15.5%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
5 Reasons to Add Kronos Worldwide Stock to Your Portfolio
Kronos Worldwide’s (KRO - Free Report) stock looks promising at the moment. The chemical maker, currently carrying a Zacks Rank #1 (Strong Buy), has seen its shares pop roughly 56% year to date. If you haven’t taken advantage of the share price appreciation yet, the time is right for you to add the stock to portfolio as it looks promising and is poised to carry the momentum ahead.
What’s Working in Favor of Kronos?
Strong Q1 Performance & Upbeat Outlook: Kronos swung to a profit of $36.8 million or 32 cents per share in first-quarter 2017 from a loss of $3.8 million or 3 cents per share a year ago. Earnings per share topped the Zacks Consensus Estimate of 22 cents.
The results in the reported quarter were boosted by higher income from operations resulting from favorable impacts of improved selling prices, increased sales and production volumes and reduced raw materials and other production costs.
Revenues climbed 16% year over year to $369.8 million in the quarter, driven by higher titanium dioxide (TiO2) selling prices and increased sales volumes. Sales also surpassed the Zacks Consensus Estimate of $350 million.
Kronos envisions its production volumes to be higher in 2017 on a year over year basis as production rates this year will be favorably impacted by the implementation of certain productivity-enhancing improvement projects at some facilities. It also sees healthy demand for its TiO2 products across some of its primary markets.
Kronos also expects income from operations in 2017 will be higher on a year over year basis, mainly due to an expected increase in average selling prices and the favorable impact of anticipated higher production volumes in 2017.
An Outperformer: Kronos has significantly outperformed the Zacks categorized Chemicals-Diversified industry over a year, partly reflecting its forecast-topping earnings performance. The company’s shares have gained a whopping 209% over this period, compared with roughly 16.2% gain recorded by the industry.
Estimates Moving Up: Annual estimates for Kronos have moved north over the past 30 days, reflecting analysts’ confidence on the stock. Over this period, the Zacks Consensus Estimate for 2017 has increased by around 13.8% to 91 cents per share. The Zacks Consensus Estimate for 2018 has also moved up 17% over the same timeframe to $1.24.
Positive Earnings Surprise History: Kronos has an impressive earnings surprise history. The company has outpaced the Zacks Consensus Estimate in three of the trailing four quarters, delivering a positive average earnings surprise of 64.14%.
Healthy Growth Prospects: The Zacks Consensus Estimate for earnings for 2017 is currently pegged at 91 cents, reflecting an expected year-over-year growth of 192.5%. Moreover, earnings are expected to register a 36.2% growth in 2018. The stock also has a long-term (3-5 years) expected earnings per share growth rate of 5%.
Kronos Worldwide Inc Price and Consensus
Kronos Worldwide Inc Price and Consensus | Kronos Worldwide Inc Quote
Other Stocks to Consider
Other top ranked stocks in the chemical space include Huntsman Corporation (HUN - Free Report) , BASF SE (BASFY - Free Report) and The Chemours Company (CC - Free Report) , all sporting a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Huntsman has an expected long-term earnings growth of 7%.
BASF has an expected long-term earnings growth of 8.6%.
Chemours has an expected long-term earnings growth of 15.5%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>